Bicara Therapeutics Inc. (BCAX) — SEC Filings
Bicara Therapeutics Inc. (BCAX) — 23 SEC filings. Latest: 8-K (May 11, 2026). Includes 9 8-K, 4 10-Q, 3 SC 13G.
View Bicara Therapeutics Inc. on SEC EDGAR
Overview
Bicara Therapeutics Inc. (BCAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: Bicara Therapeutics Inc. filed an 8-K on March 30, 2026, reporting its financial results for the period ending March 30, 2026. The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), with a press release for Q4 2025 attached as
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 2 bearish, 21 neutral. The dominant filing sentiment for Bicara Therapeutics Inc. is neutral.
Filing Type Overview
Bicara Therapeutics Inc. (BCAX) has filed 9 8-K, 4 10-Q, 1 DEF 14A, 3 SC 13G, 2 SC 13D, 3 S-1/A, 1 S-1 with the SEC between Aug 2024 to May 2026.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of BCAX's 18 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ -100.56M |
| EPS | $ -1.84 |
| Debt-to-Equity | 0.05 |
| Cash Position | $ 171.67M |
| Operating Margin | N/A |
| Total Assets | $ 424.68M |
| Total Debt | $ 21.91M |
Key Executives
- Peter Kolchinsky
- David Bonderman
- James G. Coulter
- Jon Winkelried
- Bradford Berenson
- Claire Mazumdar
- Lara Meisner
- Kingsley L. Taft
- Gabriela Morales-Rivera
- Amarilice Young
Industry Context
Bicara Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on oncology. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies in this space often rely on successful clinical trial outcomes and subsequent regulatory approvals to achieve commercial success. The market for head and neck squamous cell carcinoma (HNSCC) treatments is evolving, with a continuous demand for more effective and less toxic therapies.
Top Tags
biotech (4) · sec-filing (4) · ipo (4) · 8-k (3) · Biotechnology (2) · R&D Expenses (2) · Net Loss (2) · Oncology (2) · filing (2) · 10-Q (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $100.56M | for the nine months ended September 30, 2025, a significant increase from $47.04M in 2024 |
| Total Operating Expenses | $114.48M | for the nine months ended September 30, 2025, more than double the $55.75M in 2024 |
| Research and Development Expenses | $76.78M | for the nine months ended September 30, 2025, a primary driver of increased losses |
| Cash and Cash Equivalents | $171.67M | as of September 30, 2025, down from $489.71M at December 31, 2024 |
| Common Shares Outstanding | 54,781,950 | as of November 5, 2025 |
| Interest Income | $14.08M | for the nine months ended September 30, 2025, an increase from $8.72M in 2024 |
| Net Loss (Six Months Ended June 30, 2025) | $64.234M | Increased from $29.557M in 2024, indicating widening losses. |
| Net Cash Used in Operating Activities (Six Months Ended June 30, 2025) | $53.700M | Significant cash burn, up from $27.495M in 2024. |
| Cash and Cash Equivalents (June 30, 2025) | $436.606M | Decreased from $489.711M at December 31, 2024, reflecting cash usage. |
| Research and Development Expenses (Six Months Ended June 30, 2025) | $59.131M | Major driver of increased losses, up from $27.873M in 2024. |
| Common Shares Outstanding (August 6, 2025) | 54,562,841 | Indicates potential for future dilution with additional funding needs. |
| Interest Income (Six Months Ended June 30, 2025) | $9.696M | Increased from $5.568M in 2024, providing some offset to losses. |
| Accumulated Deficit (June 30, 2025) | $285.250M | Increased from $221.016M at December 31, 2024, reflecting ongoing losses. |
| Reporting Period End Date | 2025-03-31 | Covers the first quarter of 2025 |
| Filing Date | 2025-05-13 | Date the 10-Q was submitted to the SEC |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bicara Therapeutics Inc. (BCAX)?
Bicara Therapeutics Inc. has 23 recent SEC filings from Aug 2024 to May 2026, including 9 8-K, 4 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BCAX filings?
Across 23 filings, the sentiment breakdown is: 2 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Bicara Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bicara Therapeutics Inc. (BCAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bicara Therapeutics Inc.?
Key financial highlights from Bicara Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BCAX?
The investment thesis for BCAX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bicara Therapeutics Inc.?
Key executives identified across Bicara Therapeutics Inc.'s filings include Peter Kolchinsky, David Bonderman, James G. Coulter, Jon Winkelried, Bradford Berenson and 5 others.
What are the main risk factors for Bicara Therapeutics Inc. stock?
Of BCAX's 18 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Bicara Therapeutics Inc.?
Forward guidance and predictions for Bicara Therapeutics Inc. are extracted from SEC filings as they are enriched.